Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.49 |
| ▸ | ITK | Q08881 | 3/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 4/20 | 0.46 |
| ▸ | JAK2 | O60674 | 4/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 5/20 | 0.45 |
| ▸ | SCN4A | P35499 | 3/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 4/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.43 |
| ▸ | TYK2 | P29597 | 1/20 | 0.42 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30379778 | 1.00 | JAK3 (0.49) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL25053131 | 0.82 | JAK3 (0.56) | JAK3ITKJAK1JAK2MAPKAPK2 | |
| SCHEMBL30190947 | 0.74 | JAK3 (0.68) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL24150634 | 0.74 | JAK3 (0.68) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL30190928 | 0.71 | JAK3 (0.60) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL30190927 | 0.71 | JAK3 (0.60) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL24150543 | 0.71 | JAK3 (0.60) | JAK3ITKEGFRJAK1JAK2 | |
| SCHEMBL24150811 | 0.70 | JAK3 (0.56) | JAK3ITKJAK1JAK2MAPKAPK2 | |
| SCHEMBL30190614 | 0.70 | JAK3 (0.56) | JAK3ITKJAK1JAK2MAPKAPK2 | |
| SCHEMBL24150121 | 0.70 | JAK3 (0.58) | JAK3ITKJAK1JAK2MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2023-02-16 | — | — | US | disclosed |
| WO-2021262596-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT P53 FUNCTION | PMV PHARMACEUTICALS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046427-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | JAK3 4427/4885ITK 4359/4885EGFR 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.